Posted inGenetics
Transmissible Cancer Discovered in Freshwater Fish
Scientists in Vermont have been studying catfish with mysterious black lesions—like this one. They were surprised to learn that the…
Posted inGenetics
Transcripta Bio Raises $24M for AI-Driven Neurological Disease Therapies
Transcripta Bio leverages robotic platforms to drive scalable therapeutics research [Transcripta Bio] Chris Moxham, PhD, has been a “drug hunter”…
Posted inGenetics
Hybrid Single-Use and Stainless-Steel Plants the Greener Option
Hybrid biopharmaceutical manufacturing facilities that combine stainless steel (SSTs) and single-use (SUTs) technologies are the “sweet spot” from an environmental…
Posted inGenetics
Scaling Cell and Gene Therapy Manufacturing
As cell and gene therapies (CGTs) move closer to mainstream clinical use, manufacturers are under growing pressure to bridge the…
Posted inGenetics
Cell-Therapy Manufacturers Get Creative on Checking Particulates
Manufacturers of cell-containing products are adopting new techniques to work around unclear regulatory guidance on particulates. That’s the experience of…
Posted inGenetics
AI Protein Engineering Model Designed for Biomanufacturing
A cell engineering model designed specifically for the biomanufacturing environment could go a long way toward optimizing host cell performance,…
Posted inGenetics
Engitix Licenses Lonza’s Technology to Advance ADC Therapies
Credit: Sanjeri/Getty Images Lonza and Engitix signed a licensing agreement to advance the development of antibody-drug conjugates (ADCs) as therapies…
Posted inResearch
House passes bill directing FDA to update animal testing rules
The U.S. House of Representatives passed the FDA Modernization Act 3.0 this week, and lawmakers and animal welfare advocates are…
Posted inBiotechnology
Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug
Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for…
Posted inBiotechnology
Celldex ends skin disease program after failing phase 2 test
A phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech…